Algert Global LLC Sells 30,945 Shares of Haemonetics Co. (NYSE:HAE)

Algert Global LLC lessened its position in Haemonetics Co. (NYSE:HAE - Free Report) by 57.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,972 shares of the medical instruments supplier's stock after selling 30,945 shares during the period. Algert Global LLC's holdings in Haemonetics were worth $1,900,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company increased its position in Haemonetics by 327.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 307,564 shares of the medical instruments supplier's stock valued at $25,445,000 after acquiring an additional 235,535 shares during the period. Deerfield Management Company L.P. Series C bought a new stake in shares of Haemonetics in the second quarter worth $499,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Haemonetics in the second quarter valued at $140,000. Point72 Hong Kong Ltd bought a new position in Haemonetics during the 2nd quarter worth $959,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Haemonetics during the 2nd quarter worth about $1,925,000. 99.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Haemonetics

In other news, EVP Anila Lingamneni sold 2,136 shares of the company's stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $90.00, for a total value of $192,240.00. Following the completion of the sale, the executive vice president now owns 21,410 shares of the company's stock, valued at approximately $1,926,900. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Haemonetics news, insider Stewart W. Strong sold 4,312 shares of the firm's stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $91.15, for a total transaction of $393,038.80. Following the completion of the transaction, the insider now owns 18,196 shares of the company's stock, valued at $1,658,565.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Anila Lingamneni sold 2,136 shares of the stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $90.00, for a total value of $192,240.00. Following the sale, the executive vice president now owns 21,410 shares in the company, valued at $1,926,900. The disclosure for this sale can be found here. Insiders own 1.80% of the company's stock.

Haemonetics Stock Down 1.6 %

NYSE HAE traded down $1.23 on Thursday, hitting $78.08. 373,746 shares of the company were exchanged, compared to its average volume of 544,096. The company has a current ratio of 3.76, a quick ratio of 2.33 and a debt-to-equity ratio of 1.35. The company has a market cap of $3.98 billion, a PE ratio of 34.63, a PEG ratio of 1.19 and a beta of 0.30. The stock has a fifty day moving average of $78.24 and a 200-day moving average of $84.04. Haemonetics Co. has a 12 month low of $70.74 and a 12 month high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing the consensus estimate of $1.03 by ($0.01). The firm had revenue of $336.17 million during the quarter, compared to analyst estimates of $335.08 million. Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The business's quarterly revenue was up 8.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.05 earnings per share. As a group, analysts forecast that Haemonetics Co. will post 4.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on HAE. Needham & Company LLC raised Haemonetics from a "hold" rating to a "buy" rating and set a $112.00 price target for the company in a research note on Wednesday, June 12th. JMP Securities restated a "market outperform" rating and set a $125.00 price target on shares of Haemonetics in a report on Tuesday, August 13th. CL King initiated coverage on shares of Haemonetics in a research report on Friday, September 13th. They issued a "buy" rating and a $116.00 price target on the stock. Bank of America started coverage on shares of Haemonetics in a research report on Wednesday, September 11th. They set a "neutral" rating and a $85.00 price objective for the company. Finally, Citigroup dropped their target price on shares of Haemonetics from $94.00 to $85.00 and set a "neutral" rating on the stock in a report on Thursday, August 22nd. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $106.14.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.